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Herpes simplex virus type 1 (HSV-1) is an important human pathogen and a leading cause of
infectious blindness in the developed world. HSV-1 exploits heparan sulfate proteoglycans
(HSPG) for attachment to cells. While the significance of heparan sulphate (HS) moieties in HSV-1
infection is well established, the role of specific proteoglycan core proteins in the infection process
remains poorly understood. The objective of this study was to assess the roles of syndecan-1 and
syndecan-2 core proteins in HSV-1 infection, both of which are expressed by many HSV-1 target
cell types. Our results demonstrate that syndecan-1 and syndecan-2 gene silencing by RNA
interference reduces HSV-1 entry, plaque formation and facilitates cell survival. Furthermore, HSV-1
infection increases syndecan-1 and syndecan-2 protein synthesis and a resultant increase in cell
surface expression of HS. Our observations suggest that changes in syndecan-1 and syndecan-2
expression levels may be related to active viral infection. Taken together, our findings provide new
insights into HSPG functions during HSV-1 entry and spread.
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is a clinically
important pathogen and a leading cause of infectious
blindness in the developed world. HSV-1 productively
infects epithelial cells and establishes latent infection in
sensory ganglia for the life of the host (Kumaraguru &
Rouse, 2002; Terasaka et al., 2010). Currently, no cure
exists against HSV-1, which can be transmitted via
asymptomatic shedding by latently infected individuals
(Hill & Clement, 2009). Prevention of virus transmission to
uninfected people is a real challenge compounded by our
limited understanding of HSV-1–host cell interactions
including virus entry, which is the first essential step for the
establishment of an acute and/or latent infection.
Enveloped viruses including HSV-1 penetrate host cells by
inducing fusion between the virus envelope and the host cell
membrane. HSV-1 entry is a stepwise process, which starts
when HSV-1 envelope glycoproteins gB and gC attach to cell
surface heparan sulfate proteoglycans (HSPGs) (Herold
et al., 1991; Nicola et al., 2003; Trybala et al., 2000). This
initial interaction enables HSV-1 glycoprotein D (gD) to
bind to one of the known gD entry co-receptors. There are
three classes of gD co-receptors that have been characterized:
nectin-1 (HveC) and nectin-2 (HveB), which are both
members of the immunoglobulin superfamily (Geraghty
et al., 1998), herpesvirus entry mediator (HVEM) that
belongs to the tumour necrosis factor receptor family
(Montgomery et al., 1996), and 3-O-sulfated heparan sulfate
(3-OS HS) which is a specifically modified form of heparan
sulfate (HS) (Shukla et al., 1999b; O’Donnell et al., 2010).
The binding of gD to one of its receptors leads to confor-
mational changes in gD that allows it to activate a multi-
glycoprotein complex involving gB, gD, gH and gL that
triggers the viral fusion with the host cell membrane (Atanasiu
et al., 2007; Spear et al., 2000). This fusion mechanism is
utilized by HSV-1 when it enters the host cell by fusion with
the plasma membrane, or when using different entry pathways,
including endocytosis and phagocytosis (Clement et al., 2006;
Nicola et al., 2003; Reske et al., 2007; Shukla & Spear, 2001).
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The HS is a glycosaminoglycan (GAG) that is present in
almost all mammalian tissues on cell surfaces and in the
extracellular matrix (Esko & Lindahl, 2001; Lindahl et al.,
1998). HS commonly occurs as proteoglycans, where HS
GAG chains are attached to a core protein via a
trisaccharide linkage on a serine residue forming the
HSPG (O’Donnell & Shukla, 2008). The syndecan family is
one of the most abundant HSPGs expressed on mam-
malian cells (Muto et al., 2007; Schofield et al., 1999;
Tumova et al., 2000). There are four members in the
syndecan family (syndecan-1, 2, 3 and 4) composed of a
single membrane-spanning protein, a conserved trans-
membrane domain, and an extracellular domain that is
specific for each syndecan (Beauvais et al., 2004). The
divergent ectodomains share conserved attachment sites
for GAG chains. These GAGs are predominantly heparan
sulfated (Carey, 1997; Lopes et al., 2006) but syndecan-1
and syndecan-4 can also contain chondroitin sulfate (CS)
GAGs in addition to HS-GAGs (Deepa et al., 2004;
Shworak et al., 1994). HSV-1 commonly infects epithelial
cells, which express detectable amounts of syndecan-1 and
syndecan-2 (Bobardt et al., 2007; Cheshenko et al., 2007).
In addition, syndecan-1 (CD138; NCBI reference sequence:
NP_001006947) is expressed by many cell types including
plasma cells. Syndecan-2 (fibroglycan; NCBI reference
sequence: NP_002989) shows somewhat restricted expres-
sion, limited mainly to fibroblasts and neurons (Ethell et al.,
2001; Shimabukuro et al., 2008; Su et al., 2007). The latter
is an important site for HSV-1 latency and reactivation
(Shukla & Spear, 2001).
While studies have shown that HS plays an important role
in HSV-1 entry as an attachment receptor (Shukla & Spear,
2001), the role of specific proteoglycan core proteins in the
infection process remains poorly understood. Since
syndecan-1 and syndecan-2 are relatively common
HSPGs found on the target cell types for HSV-1 infection,
we aimed to explore the role of their core proteins in HSV-
1 infection. In this paper, we performed in vitro studies
using HeLa cells, which are known to express both HSPGs
(Brule et al., 2006; Kubo et al., 2006) to determine the
effect of syndecan-1 and syndecan-2 gene silencing on viral
entry, plaque formation and cell survival using small
interfering RNAs (siRNAs) specific for HSPGs. Since
several microbial pathogens can alter syndecan-1 expres-
sion (Anastasiadou et al., 2009; Freissler et al., 2000; Wang
et al., 2006), we also tested whether HSV-1 infection has an
effect on syndecan-1 and syndecan-2 expression in HeLa
cells. Our results provide new insights into HSPG core
protein function during HSV-1 entry and spread.
RESULTS
Syndecan-1 and syndecan-2 downregulation in
HeLa cells
The significance of syndecan-1 and syndecan-2 on HSV-1
infection was examined by selective gene silencing of
syndecan-1 and syndecan-2 in HeLa cells using siRNA
expression constructs (Beauvais et al., 2004). Cells were
treated with either syndecan-1- or syndecan-2-specific siRNA
to downregulate syndecan-1 and syndecan-2 gene expres-
sion, respectively. Gene silencing of syndecan-1 (Fig. 1a) and
syndecan-2 (Fig. 1b) was detected at the protein level by
using Western blot analysis. Densitometric analysis showed
that treatment with syndecan-1- and syndecan-2-specific
siRNA resulted in a significant (about 50 %) reduction in
syndecan-1 and syndecan-2 protein expression, respectively.
The 50 % decrease in expression corresponded well with
45–50 % transfection efficacy seen with HeLa cells in our
experiments. The effect of siRNA was specific since
scrambled siRNA failed to bring down syndecan expression
and likewise, neither scrambled nor syndecan-specific
siRNAs had any effects on b-actin expression. Additional
experiments (data not shown) demonstrated that siRNA
against syndecan-1 was specific to its subtype and did not
interfere with the expression of syndecan-2 and vice versa
syndecan-2 siRNA also demonstrated high specificity.
Downregulation of syndecan-1 and syndecan-2
inhibits HSV-1 entry
After verifying syndecan-1 and syndecan-2 downregulation
by siRNA transfection, the effect of reduced syndecan-1
and syndecan-2 protein levels on HSV-1 entry into HeLa
cells was examined. A previously described HSV-1 entry
assay (Akhtar et al., 2008; Tiwari et al., 2006) was used to
compare viral entry into cells treated with syndecan-1 or
syndecan-2 siRNA with those treated with scrambled
siRNA or mock treated. HeLa cells were infected with a
recombinant b-galactosidase expressing HSV-1 (KOS)
gL86 reporter virus. The entry of HSV-1 was measured
after 6 h of viral infection. As indicated in Fig. 2(a), a
statistically significant, 26.6±4.6 % inhibition of HSV-1
entry was observed in cells transfected with syndecan-1
siRNA (P,0.05). Transfected cells with syndecan-2 siRNA
resulted in even more significant, 64.9±5.5 % inhibition of
HSV-1 entry (P,0.0001) (Fig. 2b).
Anti-syndecan-1 and anti-syndecan-2 polyclonal
antibodies (pAbs) block HSV-1 entry
To confirm the role of syndecan-1 and syndecan-2 in HSV-
1 entry and to determine whether reduced HSV-1 entry
after syndecan-1 and syndecan-2 knockdown is specific to
syndecan ectodomains, a previously described antibody
blocking assay (Shukla et al., 1999a) and pAbs blocking
syndecan-1 and syndecan-2 ectodomains were utilized. As
shown in Fig. 3, pAbs specific for the extracellular region of
syndecan-1 or syndecan-2 were able to block HSV-1 entry
into HeLa cells in a dose-dependent manner. At the
maximum pAb concentration (4 mg per well) the observed
inhibitions were 35.7±4.2 and 57.84±6.5 %, respectively,
compared with HeLa cells that were treated with a control,
anti-myc mAb. Although both syndecan-1 and syndecan-2
pAbs reduced HSV-1 entry, syndecan-2 pAbs blockade had
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a statistically significant reducing effect (P,0.05) that was
more substantial than that caused by syndecan-1 pAbs
treatment. The effect of the pAbs was not additive since a
cocktail containing both antibodies did not enhance
inhibition beyond what was seen with syndecan-2 pAbs
(data not shown).
Downregulation of syndecan-1 and syndecan-2
inhibits plaque formation, reduces the size of
HSV-1 plaques and enhances cell survival
The ability of HSV-1 to form plaques reflects its ability to
enter cells, replicate and spread to infect neighbouring
uninfected cells. Since the downregulation of syndecan-1
and syndecan-2 reduced HSV-1 entry, we sought to determine
whether a similar decrease in HSV-1 plaque formation and
spread in HeLa cells is also observed after syndecan-1 and
syndecan-2 downregulation after siRNA transfection. A
standard plaque assay (Akhtar et al., 2008) was performed.
As shown in Fig. 4(a), there was a clear and significant
reduction in the number of plaques formed in HeLa cells
transfected with syndecan-1- and syndecan-2-specific siRNAs
compared with mock treated or scrambled siRNA-transfected
cells. Transfection with syndecan-1-specific siRNA reduced
plaque number by 63.22±2.65 % (P,0.0001), while transfec-
tion with syndecan-2-specific siRNA reduced plaque number
by 98.73±5.78 % (P,0.0001). Images taken of the plaques
formed, show that the downregulation of syndecan-1 and
syndecan-2 resulted in smaller plaques compared with the
plaques formed in mock-treated or scrambled siRNA-treated
cells (Fig. 4b).
To prove that the reduction in entry and plaque formation
is syndecan downregulation specific, and not a result of
more cell death, dead cells in each condition were counted
120 h after HSV-1 infection and the numbers were
normalized to those observed with mock-treated cells. As
shown in Fig. 4(c), downregulation of syndecan-1 reduced
the percentage of dead cells after HSV-1 infection (by
33.06±5.89 %), and downregulation of syndecan-2
resulted in a statistically significant decline in the
percentage of dead cells (by 80.45±5.68 %, P,0.05).
HSV-1 infection in HeLa cells enhances syndecan-1
and syndecan-2 cell surface expression
Earlier reports have established that infection with
microbial pathogens can result in remarkable changes in
Fig. 1. Western blot analysis of syndecan-1
and syndecan-2 protein expression after
siRNA downregulation. Protein expression of
syndecan-1 and syndecan-2 measured in a
sample of HeLa cells mock treated (no
transfection) or treated with scrambled
siRNA, syndecan-1 siRNA or syndecan-2
siRNA for 48 h. Representative Western blots
showed knockdown of syndecan-1 (a) or
syndecan-2 (b) after siRNA downregulation.
Densitometric analysis revealed 50 % reduc-
tion in the signal intensity of both syndecan-1
and syndecan-2. b-Actin protein expression
was measured as the loading control.
Representative blots from three independent
experiments are shown. The results are
expressed as means±SD values from three
independent experiments.
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syndecan expression (Magalhães et al., 2009). To determine
whether HSV-1 infection affects cell surface expression of
syndecan-1 and syndecan-2, the expression level of
syndecan-1 and syndecan-2 on HeLa cell surface was
analysed at various times after HSV-1(KOS) infection by
flow cytometry. Cell surface syndecan-1 and syndecan-2 in
uninfected HeLa cells were used as controls. As shown in
Fig. 5, both syndecan-1 and syndecan-2 cell surface
expressions were significantly upregulated as soon as 2 h
after HSV-1 infection. The increases were also observed at
4 and 6 h post-infection in HeLa and CHO-K1 cells.
HSV-1 infection in HeLa cells enhances
syndecan-1 and syndecan-2 protein synthesis
Since HSV-1 infection enhances syndecan-1 and syndecan-
2 cell surface expression, this enhancement could be a
result of more protein synthesis or a higher redistribution
of HSPGs on the cell surface. To determine if HSV-1
infection modulated syndecan-1 and syndecan-2 expres-
sion at the protein level, Western blot analysis was
performed on HeLa cells. Mock-infected cells were used
as control. Densitometric analysis showed that the
syndecan-1 protein expression level was increased by
1.64±0.16-fold at 2 h and 2.01±0.16-fold at 6 h after
HSV-1 infection (Fig. 6a). Syndecan-2 protein expression
level was also increased by 2.59±0.64-fold at 2 h and
3.16±1.02-fold at 6 h after HSV-1 infection (Fig. 6b).
These results demonstrate that HSV-1 not only enhances
the cell surface distribution of syndecans, but also induces
syndecan-1 and syndecan-2 protein synthesis.
Fig. 2. Downregulation of syndecan-1 and syndecan-2 inhibits
HSV-1 entry into HeLa cells. HSV-1 entry was analysed in HeLa
cells mock treated (no transfection) or transfected with scrambled
siRNA, syndecan-1 siRNA or syndecan-2 siRNA. After siRNA
transfection (48 h), cells were inoculated with a serial dilution of b-
galactosidase-expressing recombinant HSV-1 (KOS) gL86 virus
for 6 h. The soluble substrate ONPG was added and enzymic
activity was measured. Downregulation of both syndecan-1 (Fig.
2a) and syndecan-2 (Fig. 2b) inhibits HSV-1 (KOS) gL86 entry
into HeLa cells although syndecan-2 siRNA has more significant
effect. Per cent inhibition of HSV-1(KOS) gL86 entry by syndecan-
1 siRNA or syndecan-2 siRNA treatment was calculated relative to
mock-treated (no transfection) cells. Scrambled siRNA-trans-
fected cells were used as negative control. Each value shown is
the mean of six determinations (±SD) (*P,0.05, **P,0.0001).
Fig. 3. Syndecan-1- or syndecan-2-specific antibody treatment
blocked HSV-1(KOS) gL86 entry into HeLa cells. Cells were
incubated with a serial dilution of syndecan-1-specific pAbs,
syndecan-2-specific pAbs, or control anti-myc mAb for 30 min.
Cells were then inoculated with a constant dose of b-galactosi-
dase-expressing recombinant HSV-1(KOS) gL86 (m.o.i. of 10) for
2 h. The soluble substrate ONPG was added and enzymic activity
was measured. Per cent inhibition of HSV-1(KOS) gL86 entry by
syndecan-1 pAbs or syndecan-2 pAbs treatment was calculated
relative to anti-myc mAb-treated cells. Each value shown is the
mean of four determinations (±SD) (P,0.05).
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HSV-1 infection causes an increase of HS
expression on cell surface
Finally, since HSV-1 infection of host cell results in an
upregulation of syndecan cell surface and protein expres-
sion, we wanted to determine whether this may lead to an
upregulation of HS as well. To investigate if HSV-1
infection affects HS cell surface expression, flow cytometry
analysis was performed. At 2 h post-infection, HS surface
expression increased in cells treated with HSV-1(KOS)
compared to those that are mock treated (Fig. 7). However,
at later time points, HS surface expression increased at a
slower rate compared with the pattern that was observed
for syndecan-1 and syndecan-2 upregulation after HSV-1
treatment. It is therefore likely that the core proteins may
be synthesized at a higher rate than HS and this result may
suggest an HS-independent function of the syndecan core
proteins in the infection process.
DISCUSSION
HS is expressed on the cell surface of most mammalian cell
types as HSPGs, and can serve as a receptor for a wide
range of microbial pathogens, including viruses and
bacteria (Barth et al., 2003; Giroglou et al., 2001;
Menozzi et al., 2006; Smith et al., 2006). Although the
role of HS is well studied as an attachment receptor for
HSV-1, the role of HSPG core proteins in HSV-1 infection
is poorly understood. This study is the first of its kind that
directly implicates two members of the syndecan family of
HSPGs, syndecan-1 and syndecan-2, as important media-
tors of HSV-1 infection. We demonstrate that both of them
contribute significantly to viral entry and spread. Knocking
down of either syndecan-1 or syndecan-2 shows detectable
effects on HSV-1 entry and plaque formation. Our results
Fig. 4. Downregulation of syndecan-1 and syndecan-2 affects
HSV-1 plaque formation, size and enhances cell survival in HeLa
cells. Cells were either mock treated (no transfection), or treated
with scrambled siRNA, syndecan-1 siRNA or syndecan-2 siRNA.
Post-transfection cells (48 h) were infected with HSV-1(KOS)
(m.o.i. of 0.01). (a) Post-infection infectivity at 72 h was measured
by the number of p.f.u. Relative number of plaques was computed
relative to mock-treated (no transfection) samples. Significant
decreases of number of plaques were seen in both syndecan-1
siRNA- and syndecan-2 siRNA-transfected HeLa cells. Plaques
that consisted of 15 or more nuclei were counted. Results are
means±SD of four independent experiments conducted in
triplicate (**P,0.0001). (b) Morphological appearance of
Giemsa-stained HSV-1 (KOS) plaques 72 h post-infection. In
syndecan-1 siRNA- and syndecan-2 siRNA-treated HeLa cells
smaller plaques were observed compared with the plaques in
mock-treated or scrambled siRNA-treated cells. Magnification,
40. (c) Cytotoxicity was measured after 120 h HSV-1 (KOS)
infection. Relative number of dead cells was calculated relative to
mock-treated samples. Significant decreases of cytotoxicity were
observed in both syndecan-1 siRNA- and syndecan-2 siRNA-
treated cells; however, only the effect of syndecan-2 siRNA
treatment was statistically significant. Results are means±SD of
four independent experiments conducted in triplicate (*P,0.05).
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also suggest that syndecan-2 may have a distinctly larger
role in HSV-1 infection than syndecan-1.
In addition, we provide evidence to directly implicate the
HSPG core protein in viral entry. Many known protein
receptors for HSV-1 entry can be blocked by antibodies,
which in turn, blocks viral entry (Akhtar et al., 2008;
Shukla et al. 2009). Similar to those receptors, we also
found that pAbs against synedecan-1 and syndecan-2 block
entry. While it is quite possible that antibodies may act by
producing steric hinderance to virus binding via HS, it is
also possible that the core protein may directly interact
with HSV-1 glycoproteins and that interaction is blocked
by the antibodies. For unclear reasons the syndecan pAbs
when combined together did not produce an additive
effect. Future studies will determine whether the syndecan
pAbs (especially syndecan-2 pAbs) may cross-react to block
certain conserved syndecan epitopes shared for entry. In
this case, one group of pAbs (e.g. syndecan-2 pAbs) may be
able to block all the epitopes (whether on syndecan-1 or
syndecan-2) and therefore, pAbs to another protein may
not be able to show any additional effects. Alternatively, a
second possibility is that the pAbs may be able to block low
affinity interactions (or create steric hindrance) that do not
involve conformational changes. However, high affinity
interactions (accompanied by conformation changes) may
not be blocked by antibodies and therefore, the net effect
by combining the antibodies may not be significantly
higher than individual effects. This may be a reason why a
near complete blocking of HSV-1 infection by antibodies
has been extremely rare even when all gD receptors were
blocked (Akhtar et al., 2008; Shukla et al. 2009). Our
results, nevertheless, highlight that syndecan-1 and synde-
can-2 play a critical role during HSV-1 entry and that the
two HSPGs show detectable differences in their abilities to
facilitate infection.
A related interesting finding was that the effect of
syndecan-2 knockdown was even more severe at the plaque
formation level. Unlike entry, the downregulation of
syndecan-2 expression almost completely inhibited plaque
formation in HeLa cells. A reduction in plaque number was
expected since we found that downregulation of syndecan-
1 and syndecan-2 reduces HSV-1 entry. However, the
observed dramatic reduction in plaque formation raises the
possibility that reduced virus entry may not be the only
reason for reduced plaque formation and that an additional
role for syndecan-2 in HSV-1 replication or spread could
not be ruled out. Since syndecans participate in endocy-
tosis, they may affect virus transport as well (Fuki et al.,
2000).
One possible way to explain the fact that syndecan-2 has a
more significant role in HSV-1 entry is related to the
differences in GAG distribution on the ectodomains of the
HSPGs. While the syndecan-1 ectodomain carries HS and
chondroitin sulfate (CS) chains, syndecan-2 carries solely
HS chains on its ectodomain (Rapraeger et al., 1985;
Shworak et al., 1994; Su et al., 2007). It is possible that the
presence of HS alone may help reduce any non-specific
virus binding generated by similarly charged but less
effective CS. A second way to explain the observable
differences relies on HSPG cytoplasmic domain that has
been shown to interact with a variety of signalling and
structural proteins, suggesting its involvement in various
regulatory phenomena. The cytoplasmic domain consists
of two conserved regions, a membrane proximal com-
mon region (C1) and C-terminal common region (C2).
C2 mediates binding to cytoskeletal proteins and to
Fig. 5. HSV-1 infection of host cell enhances syndecan-1 and
syndecan-2 cell surface expression in HeLa cells. Cells were
infected with a constant dose of HSV-1 (KOS) (m.o.i. of 10) for 2,
4 or 6 h. Syndecan-1 and syndecan-2 cell surface expression was
then detected by FACS analysis. Enhanced syndecan-1 (a) and
syndecan-2 (b) cell surface expression was detected when HeLa
cells were infected with HSV-1. Mock-infected FITC stained cells
were used as background control. Results are representative of
three independent experiments.
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PDZ-containing proteins (Couchman, 2003; Grootjans
et al., 1997; Lopes et al., 2006). The C1 and C2 conserved
regions are separated by a variable region (V) that is unique
for each of the four syndecan family members (Couchman,
2003; Lopes et al., 2006). The difference in the variable
region in syndecan-1 and syndecan-2 might explain how
these two syndecans might have different regulatory roles
during HSV-1 infection through activating different
cellular pathways.
Previous studies have shown that the infection with various
microbial pathogens can modulate the expression levels of
different syndecan family members. For example, altera-
tions in syndecan-1 expression level are observed during
the infection with Pneumocystis jiroveci and Neisseria
gonorrhoeae (Freissler et al., 2000; Wang et al., 2006).
Epstein–Barr virus infection results in the downregulation
of syndecan-1 (Anastasiadou et al., 2009). Our study is the
first report of HSV-1 infection modulating the expression
levels of syndecan-1 and syndecan-2 in infected cells. We
demonstrated here that HSV-1-induced syndecan-1 and
syndecan-2 expression enhancements occur both at the cell
surface level and also at the protein synthesis level.
Interestingly, our findings suggest that an increase in
syndecan-1 and syndecan-2 expression levels, although
important for many reasons, may also be used as a marker
for active HSV-1 infection. Further experiments are needed
to understand mechanisms by which HSV-1 upregulates
syndecan-1 and syndecan-2 expression and to determine
Fig. 6. Western blot analysis of syndecan-1
and syndecan-2 protein expression after HSV-
1 (KOS) infection. HeLa cells were infected
with a constant dose of HSV-1 (KOS) (m.o.i. of
10) for 2 and 6 h. Cell lysates were then
blotted against syndecan-1 and syndecan-2.
According to the densitometric analysis syn-
decan-1 (a) and syndecan-2 (b) were more
strongly expressed at 2 and 6 h post-infection
compared with the uninfected cells in HeLa
cells. Relative intensity of HSV-1(KOS) virus-
infected bands expressed as a ratio relative to
the mock-infected sample is shown. b-Actin
protein expression was measured as loading
control. The results are expressed as
means±SD values from three independent
experiments.
Fig. 7. Flow cytometry analysis of HS expression on HeLa cells
infected with HSV-1. HeLa cells were infected with HSV-1(KOS)
(m.o.i. of 10) at 37 6C for 2, 4 or 6 h. HS cell surface expression
was then detected by FACS analysis. In HSV-1-infected cells, HS
cell surface expression was enhanced compared with uninfected
cells. Untreated FITC stained HeLa cells were used as background
control.
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whether this upregulation is a result of specific signalling
pathway activation by the virus. Further understanding of
the role of the syndecans in HSV-1 infection could identify
novel antiviral targets and lead to the development of
improved antiviral strategies.
METHODS
Cells and viruses. African green monkey kidney cells (Vero), gL-
expressing Vero cells (79B4) and Chinese hamster ovarian-K1 (CHO-
K1) cells were provided by P. G. Spear (North-western University,
Chicago, IL, USA). Human cervical (HeLa) cells were obtained from
B. P. Prabhakar (University of Illinois at Chicago, Chicago, IL, USA).
HeLa, Vero and gL-expressing Vero cells (79B4) were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL) supple-
mented with 10 % FBS and 100 mg l21 of penicillin/streptomycin
(P/S). CHO-K1 cells were grown in Ham’s F-12 medium (Gibco-
BRL) supplemented with 10 % FBS and P/S. The b-galactosidase
expressing recombinant HSV-1 (KOS) gL86 and wild-type HSV-1
(KOS) viruses were provided by P. G. Spear (North-western Univer-
sity, Chicago, IL, USA). HSV-1 (KOS) K26GFP was provided by
P. Desai (Johns Hopkins University, Baltimore, MD, USA). Jellyfish
GFP was fused in-frame with the UL35 ORF generating K26GFP virus
whose capsids express GFP (Desai & Person, 1998). Virus stocks were
propagated in complementing cell lines and stored at 280 uC. Yields
of infectious virus titre (p.f.u. ml21) were determined by plaque assay
in Vero cells.
Antibodies and enzymes. Antibodies and their dilutions were as
follows: anti-syndecan-1 mouse mAbs diluted at 1 mg per 16106 cells
(Santa Cruz Biotechnology); anti-syndecan-2 rat mAbs 1.25 mg per
16106 cells (R&D Systems); anti-heparan sulfate mouse mAb (10E4
epitope) diluted 1 : 50 (US Biological); anti-syndecan-1 rabbit pAb
diluted 1 : 500 (Santa Cruz Biotechnology); anti-syndecan-2 rabbit
pAb diluted 1 : 500 (Santa Cruz Biotechnology); anti-b-actin mouse
mAb diluted 1 : 1000 (Sigma-Aldrich); and anti-myc mouse mAb
(Invitrogen). The secondary antibodies for flow cytometry were
FITC-conjugated anti-mouse secondary antibody diluted 1 : 100
(Sigma-Aldrich); FITC-conjugated anti-rat secondary antibodies
diluted 1 : 100 (Sigma-Aldrich); and FITC-conjugated anti-mouse
IgM diluted 1 : 100 (Sigma-Aldrich). The secondary antibodies for
Western blots were HRP-conjugated anti-rabbit IgG diluted 1 : 20 000
(Jackson ImmunoResearch Laboratories); and HRP-conjugated anti-
mouse IgG diluted 1 : 25 000 (Jackson ImmunoResearch Laboratories).
Heparinase I, II and III enzymes were provided by Jian Liu
(University of North Carolina, Chapel Hill, NC, USA) and used at
12 mg per sample (170 mg ml21 final concentration). Chondroitinase
ABC used at 0.005 U per sample (0.1 U ml21 final concentration)
(Sigma-Aldrich).
siRNA transfections. HeLa and CHO-K1 cells were transfected at
80 % confluence with a concentration of 200 nM per well syndecan-1
siRNA (59-CCAUUCUGACUCGGUUUCU[dT][dT]-39, and 59-GCC-
AAGGUUUUAUAAGGCU[dT][dT]-39; Sigma-Aldrich), syndecan-2
siRNA (SASI_Hs01_00195372, SASI_Hs01_00195365; Sigma-Aldrich),
or non-specific, scrambled siRNA (59-GAUCAUACGUGCGA-
UCAGA[dT][dT]-39; Sigma-Aldrich). Transfection was done using
Lipofectamine 2000 reagent (Invitrogen). At 6 h after transfection,
each well was supplemented with 3 ml complete growth medium
(DMEM supplemented with 10 % FBS and P/S). Cells were analysed
for protein expression and cell surface expression 48 h after
transfection by preparing Western blots and by flow cytometry.
Transfection efficacy was measured by using a plasmid that encoded
enhanced GFP (eGFP) (Invitrogen) by counting eGFP-positive cells
by fluorescence microscopy.
Viral entry assay. Standard entry assay was used as described
previously (Shukla et al., 1999b). Briefly, HeLa cells and HSV-1 entry
receptor lacking CHO-K1 cells were plated in a 96-well tissue culture
dish at a density of 86103 cells per well. Cells were transfected with
syndecan-1, syndecan-2 or scrambled siRNA as described above. After
48 h, cells were infected with the b-galactosidase expressing
recombinant HSV-1(KOS) gL86 in a twofold serial dilution for 6 h
at 37 uC. b-Galactosidase expression can be induced by early viral
protein synthesis upon HSV infection (Copeland et al., 2008). At 6 h
post-infection, cells were washed twice with PBS and the soluble
substrate O-nitrophenyl-b-D-galactopyranoside (ONPG; Pierce) was
added. Enzymic activity was measured at 410 nm using a micro-plate
reader (Spectra Max 190 Molecular Devices).
Antibody blocking assay. Standard antibody blocking assay was
used as described previously (Shukla et al., 1999a). Briefly, confluent
HeLa cells in 96-well tissue culture dish were washed with PBS and
incubated with serial dilutions of rabbit pAbs to sydecan-1, syndecan-
2 (Santa Cruz Biotechnology) or control anti-myc mAb (Invitrogen)
for 30 min at 37 uC. A constant dose of HSV-1(KOS) gL86 (m.o.i. of
10) was then added to all wells for 2 h at 37 uC. After 2 h, cells were
washed and bound virus was removed by 20 s treatment with
100 mM citrate buffer (pH 3.0). Incubation was then continued for
another 3 h. Cells were then washed twice with PBS, and b-
galactosidase activity was measured by adding its substrate ONPG
as described in virus entry assay.
Plaque assay. Viral replication upon syndecan-1 and syndecan-2
knockdown was assessed by a plaque assay (Akhtar et al., 2008;
Tiwari et al., 2006). In brief, monolayers of HeLa cells plated in
six-well tissue culture dishes were transfected with syndecan-1,
syndecan-2 or scrambled siRNA as described above. At 48 h post-
transfection, cells were infected (m.o.i. of 0.01) with HSV-1 (KOS)
or mock infected in PBS for 90 min at 37 uC. Cells were then washed
with PBS, and fresh medium (DMEM supplemented with 10 % FBS
and P/S) was added. Cells were incubated for 72 h at 37 uC. After
72 h, cells were washed with PBS, fixed with 100 % methanol for
5 min, and stained with the Giemsa stain (Sigma-Aldrich) for
20 min. Infectivity was measured by counting plaques formed using
610 objective lens of an inverted light microscope (Zeiss Axiovert
200).
Cytotoxicity assay. Confluent monolayer of HeLa cells was
transfected with syndecan-1, syndecan-2 or scrambled siRNA as
described above. In addition to the non-specific, scrambled siRNA-
transfected cells, non-transfected cells were used as a control. After
48 h post-transfection, cells were infected with HSV-1(KOS) (m.o.i.
of 0.01) for 90 min at 37 uC. The inoculum was then removed by
washing the cells with PBS and fresh medium was added. Cells were
incubated at 37 uC for 120 h, then fixed with 100 % methanol and
stained with Giemsa stain. The number of dead cells was counted
using NIH Image J software (version: 1.43) at twenty high power
fields (640 objective).
Flow cytometry. Syndecan-1 and syndecan-2, and HS cell surface
expression was detected after HSV-1(KOS) infection. For syndecan-
1 and syndecan-2 cell surface expression, confluent monolayer of
HeLa cells were infected with HSV-1 (KOS) (m.o.i. of 10) for 0, 2, 4
and 6 h. Cells were then washed with PBS, harvested, and incubated
with the respective primary antibody (syndecan-1 at 1 mg per
16106 cells, or syndecan-2 at 1.25 mg per 16106 cells) diluted in
PBS with 1 % BSA for 1 h. After primary antibody incubation, cells
were washed and incubated for 45 min with anti-mouse or anti-rat-
FITC-conjugated secondary anti-IgGs (1 : 100). Cells stained only
with anti-mouse-FITC or anti-rat-FITC was used as background
control. For HS cell surface expression, HeLa cells were infected
with HSV-1 (KOS) (m.o.i. of 10) for 0, 2, 4 and 6 h. Cells were then
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washed with PBS, harvested and incubated with mouse anti-human
HS mAb 10E4 diluted 1 : 50 (US Biological) for 20 min at 4 uC.
After that the cells were washed and incubated for 30 min at 4 uC
with FITC-conjugated anti-mouse IgM diluted to 1 : 100. Cells
stained only with FITC-conjugated anti-mouse IgM were used as
background controls.
Immunoblotting. After 48 h post-transfection and 0, 2 and 6 h after
HSV-1(KOS) infection (m.o.i. of 10), syndecan-1 and syndecan-2
protein expression was determined by Western blot analysis. The
Western blot assay was performed according to the protocol described
previously (Burbach et al., 2003; Shukla et al., 2009). Briefly,
approximately 150–200 mg of total cell protein in lysis buffer was
incubated with 2.5 volumes of 220 uC 100 % methanol overnight at
220 uC. After treatment of 500 ml 100 % acetone for 5 min, the
protein pellet was redissolved in 100 ml heparinase buffer (0.1 M
NaOAc+0.1 mM CaOAc, pH 7.0). GAGs were digested with
heparinase I, II, III (12 mg per sample) and chondroitinase ABC
(0.005 U per sample) twice for 2.5 h to remove all GAGs. Samples
were then denatured in Laemmli Sample Buffer (Bio-Rad) with 5 %
(v/v) b-mercaptoethanol and heated to 96 uC for 10 min before
loading onto a gel. After that the samples were electrophoretically
separated on 10 % SDS-gel, transferred to nitrocellulose membrane,
blocked for 2 h at room temperature in 0.1 % TTBS (0.1 % Tween 20
in TBS) containing 5 % milk, and incubated with primary rabbit pAbs
against sydecan-1 and syndecan-2 at 1 : 500 dilutions overnight at
4 uC. The blots were rinsed five times with 0.1 % TTBS (0.1 % Tween
20 in TBS) for 5 min and incubated for 1 h at room temperature with
HRP-conjugated anti-rabbit IgG at 1 : 20 000 dilutions. Anti-b-actin
mouse mAb as the primary antibody at 1 : 1000 dilution and HRP-
conjugated anti-mouse IgG as the secondary antibody at 1 : 25 000
dilution were used for detecting b-actin loading control. The signal
was visualized with SuperSignal West Femto maximum sensitivity
substrate (Pierce) and the blots were exposed to X-ray film (Kodak)
for 2 min. Developed films were scanned and protein bands were
quantified using NIH Image J software (version: 1.42) in order to
generate statistical data for specific bands. Syndecan-1 and syndecan-
2 protein expression was quantified by calculating the relative
intensity of each syndecan-1 and syndecan-2 band relative to the
mock-treated bands.
Statistical analyses. Statistical analyses were performed with the
STATISTICA software (version 8.0) for windows. Normality was tested
using the Kolmogorov–Smirnov test. All variables were distributed
normally. Homogeneity of variance was determined using Levene’s
test and was considered violated when this test yielded P,0.05. All
variances were homogeneous. Data were assessed using ANOVA
followed by Scheffé’s post-hoc test to evaluate the effects of gene
silencing of syndecan-1 and syndecan-2 on HSV-1 viral entry, plaque
formation and cytotoxicity. *P,0.05 and **P,0.0001 were regarded
as significant differences between treated and mock-treated groups.
The results are expressed as means±SD values. Each experiment was
repeated at least three times and representative results are shown in
the figures.
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